Related Experiment Video
Updated: May 30, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
[Certolizumab pegol].
Esmeralda Delgado Frías1, José Federico Díaz González
1Servicio de Reumatología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Islas Canarias, España.
Reumatologia Clinica
|July 29, 2011
Summary
Certolizumab pegol, a novel anti-TNF biologic, effectively treats rheumatoid arthritis and Crohn's disease. This review details its structure, efficacy, and safety in rheumatoid arthritis patients.
Area of Science:
- Immunology
- Pharmacology
- Gastroenterology
Background:
- Tumor Necrosis Factor-alpha (TNF-α) is a key inflammatory cytokine implicated in autoimmune diseases.
- Biologic therapies targeting TNF-α have revolutionized the treatment of inflammatory conditions.
- Certolizumab pegol represents a specific anti-TNF agent with a unique formulation.
Purpose of the Study:
- To review the structural characteristics of certolizumab pegol.
- To summarize the clinical efficacy data of certolizumab pegol in rheumatoid arthritis (RA) and Crohn's disease.
- To present the safety profile of certolizumab pegol in RA patients.
Main Methods:
- Review of published clinical trials and scientific literature.
- Analysis of structural data regarding certolizumab pegol's composition.
- Synthesis of efficacy and safety data from controlled studies.
Main Results:
- Certolizumab pegol is a PEGylated Fab' fragment of a humanized monoclonal antibody.
- It effectively targets both soluble and membrane-bound human TNF-α.
- Clinical trials demonstrate its efficacy in treating RA and Crohn's disease.
Conclusions:
- Certolizumab pegol is a clinically effective anti-TNF agent for RA and Crohn's disease.
- Its unique structure contributes to its therapeutic profile.
- Further review of its safety data in RA patients is warranted.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...